BL
JANX icon

BFSG LLC’s Janux Therapeutics JANX Stock Holding History

BFSG LLC’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54K Hold
100
– – ﹤0.01% 711
2026
Q1 		$1.39K Hold
100
– – ﹤0.01% 689
2025
Q4 		$1.38K Hold
100
– – ﹤0.01% 665
2025
Q3 		$2.44K Hold
100
– – ﹤0.01% 637
2025
Q2 		$2.31K Hold
100
– – ﹤0.01% 603
2025
Q1 		$2.7K Hold
100
– – ﹤0.01% 589
2024
Q4 		$5.35K Sell
100
-200
-67% -$10.6K ﹤0.01% 554
2024
Q3 		$13.6K Sell
300
-100
-25% -$4.35K ﹤0.01% 473
2024
Q2 		$16.8K Buy
+400
New +$18.8K ﹤0.01% 433

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BFSG LLC's JANX Position: Q2 2026 in Review

BFSG LLC held its Janux Therapeutics (JANX) position steady in Q2 2026 at 100 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #711.

BFSG LLC first reported a position in JANX in Q2 2024 and has held it in 9 quarters since. The position peaked at $16.8K in Q2 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • BFSG LLC held 100 shares of Janux Therapeutics worth $1.54K as of Q2 2026.
  • BFSG LLC left its Janux Therapeutics share count unchanged in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #711 holding.
  • BFSG LLC first reported a position in Janux Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • BFSG LLC's Janux Therapeutics position peaked at $16.8K in Q2 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.